Cargando…

Longitudinal changes of blood parameters and weight in inoperable stage III NSCLC patients treated with concurrent chemoradiotherapy followed by maintenance treatment with durvalumab

BACKGROUND: Investigating dynamic changes in blood-parameters and weight in patients with locally advanced non-small cell lung cancer (NSCLC) receiving durvalumab maintenance therapy after chemoradiotherapy (cCRT). Laboratory outcomes were determined based on the number of durvalumab administrations...

Descripción completa

Detalles Bibliográficos
Autores principales: Guggenberger, J., Kenndoff, S., Taugner, J., Käsmann, L., Flörsch, B., Belka, C., Eze, C., Manapov, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8944024/
https://www.ncbi.nlm.nih.gov/pubmed/35331196
http://dx.doi.org/10.1186/s12885-022-09395-6
_version_ 1784673633816281088
author Guggenberger, J.
Kenndoff, S.
Taugner, J.
Käsmann, L.
Flörsch, B.
Belka, C.
Eze, C.
Manapov, F.
author_facet Guggenberger, J.
Kenndoff, S.
Taugner, J.
Käsmann, L.
Flörsch, B.
Belka, C.
Eze, C.
Manapov, F.
author_sort Guggenberger, J.
collection PubMed
description BACKGROUND: Investigating dynamic changes in blood-parameters and weight in patients with locally advanced non-small cell lung cancer (NSCLC) receiving durvalumab maintenance therapy after chemoradiotherapy (cCRT). Laboratory outcomes were determined based on the number of durvalumab administrations received. METHODS: Twenty-two patients completed platinum-based cCRT followed by maintenance treatment with durvalumab. Different parameters such as hemoglobin (Hb), leukocytes, Lactate dehydrogenase (LDH), C-reactive protein (CRP), body weight and albumin were analyzed before cCRT, after cCRT, 3, 6, 9 and 12 months after starting durvalumab maintenance. RESULTS: Sixteen (72.7%) patients were male; twelve (54.5%) and fifteen (68.2%) patients had non-squamous histology and Union for International Cancer Control (UICC) stage IIIB-C disease, respectively. Median follow-up time was 24.4 months; 12- and 18-months- progression-free and overall-survival rates were 55.0% and 45.0 as well as 90.2 and 85.0%, respectively. During maintenance treatment Hb increased by 1.93 mg/dl (17.53%) after 9 months (p < 0.001) and 2.02 mg/dl (18.46%) after 12 months compared to the start of durvalumab (p < 0.001). LDH decreased by 29.86 U/l (− 11.74%) after 3 months (p = 0.022). Receipt of at least 12 cycles of durvalumab was beneficial in terms of Hb-recovery (Hb 6 months: 12.64 vs. 10.86 [mg/dl]; Hb 9 months: 13.33 vs 11.74 [mg/dl]; (p = 0.03)). Median weight change [kilogram (kg)] was + 6.06% (range: − 8.89 − + 18.75%) after 12 months. The number of durvalumab cycles significantly correlated with total weight gain [kg] (Spearman-Rho-correlation: r = 0.502*). CONCLUSION: In the investigated cohort, no severe hematologic toxicity occurred by laboratory blood tests within 1 year of durvalumab maintenance therapy after cCRT for unresectable stage III NSCLC. Receiving at least 12 cycles of durvalumab appears to have a significant effect on recovery of hemoglobin levels and body weight. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-022-09395-6.
format Online
Article
Text
id pubmed-8944024
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-89440242022-03-25 Longitudinal changes of blood parameters and weight in inoperable stage III NSCLC patients treated with concurrent chemoradiotherapy followed by maintenance treatment with durvalumab Guggenberger, J. Kenndoff, S. Taugner, J. Käsmann, L. Flörsch, B. Belka, C. Eze, C. Manapov, F. BMC Cancer Research Article BACKGROUND: Investigating dynamic changes in blood-parameters and weight in patients with locally advanced non-small cell lung cancer (NSCLC) receiving durvalumab maintenance therapy after chemoradiotherapy (cCRT). Laboratory outcomes were determined based on the number of durvalumab administrations received. METHODS: Twenty-two patients completed platinum-based cCRT followed by maintenance treatment with durvalumab. Different parameters such as hemoglobin (Hb), leukocytes, Lactate dehydrogenase (LDH), C-reactive protein (CRP), body weight and albumin were analyzed before cCRT, after cCRT, 3, 6, 9 and 12 months after starting durvalumab maintenance. RESULTS: Sixteen (72.7%) patients were male; twelve (54.5%) and fifteen (68.2%) patients had non-squamous histology and Union for International Cancer Control (UICC) stage IIIB-C disease, respectively. Median follow-up time was 24.4 months; 12- and 18-months- progression-free and overall-survival rates were 55.0% and 45.0 as well as 90.2 and 85.0%, respectively. During maintenance treatment Hb increased by 1.93 mg/dl (17.53%) after 9 months (p < 0.001) and 2.02 mg/dl (18.46%) after 12 months compared to the start of durvalumab (p < 0.001). LDH decreased by 29.86 U/l (− 11.74%) after 3 months (p = 0.022). Receipt of at least 12 cycles of durvalumab was beneficial in terms of Hb-recovery (Hb 6 months: 12.64 vs. 10.86 [mg/dl]; Hb 9 months: 13.33 vs 11.74 [mg/dl]; (p = 0.03)). Median weight change [kilogram (kg)] was + 6.06% (range: − 8.89 − + 18.75%) after 12 months. The number of durvalumab cycles significantly correlated with total weight gain [kg] (Spearman-Rho-correlation: r = 0.502*). CONCLUSION: In the investigated cohort, no severe hematologic toxicity occurred by laboratory blood tests within 1 year of durvalumab maintenance therapy after cCRT for unresectable stage III NSCLC. Receiving at least 12 cycles of durvalumab appears to have a significant effect on recovery of hemoglobin levels and body weight. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-022-09395-6. BioMed Central 2022-03-24 /pmc/articles/PMC8944024/ /pubmed/35331196 http://dx.doi.org/10.1186/s12885-022-09395-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Guggenberger, J.
Kenndoff, S.
Taugner, J.
Käsmann, L.
Flörsch, B.
Belka, C.
Eze, C.
Manapov, F.
Longitudinal changes of blood parameters and weight in inoperable stage III NSCLC patients treated with concurrent chemoradiotherapy followed by maintenance treatment with durvalumab
title Longitudinal changes of blood parameters and weight in inoperable stage III NSCLC patients treated with concurrent chemoradiotherapy followed by maintenance treatment with durvalumab
title_full Longitudinal changes of blood parameters and weight in inoperable stage III NSCLC patients treated with concurrent chemoradiotherapy followed by maintenance treatment with durvalumab
title_fullStr Longitudinal changes of blood parameters and weight in inoperable stage III NSCLC patients treated with concurrent chemoradiotherapy followed by maintenance treatment with durvalumab
title_full_unstemmed Longitudinal changes of blood parameters and weight in inoperable stage III NSCLC patients treated with concurrent chemoradiotherapy followed by maintenance treatment with durvalumab
title_short Longitudinal changes of blood parameters and weight in inoperable stage III NSCLC patients treated with concurrent chemoradiotherapy followed by maintenance treatment with durvalumab
title_sort longitudinal changes of blood parameters and weight in inoperable stage iii nsclc patients treated with concurrent chemoradiotherapy followed by maintenance treatment with durvalumab
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8944024/
https://www.ncbi.nlm.nih.gov/pubmed/35331196
http://dx.doi.org/10.1186/s12885-022-09395-6
work_keys_str_mv AT guggenbergerj longitudinalchangesofbloodparametersandweightininoperablestageiiinsclcpatientstreatedwithconcurrentchemoradiotherapyfollowedbymaintenancetreatmentwithdurvalumab
AT kenndoffs longitudinalchangesofbloodparametersandweightininoperablestageiiinsclcpatientstreatedwithconcurrentchemoradiotherapyfollowedbymaintenancetreatmentwithdurvalumab
AT taugnerj longitudinalchangesofbloodparametersandweightininoperablestageiiinsclcpatientstreatedwithconcurrentchemoradiotherapyfollowedbymaintenancetreatmentwithdurvalumab
AT kasmannl longitudinalchangesofbloodparametersandweightininoperablestageiiinsclcpatientstreatedwithconcurrentchemoradiotherapyfollowedbymaintenancetreatmentwithdurvalumab
AT florschb longitudinalchangesofbloodparametersandweightininoperablestageiiinsclcpatientstreatedwithconcurrentchemoradiotherapyfollowedbymaintenancetreatmentwithdurvalumab
AT belkac longitudinalchangesofbloodparametersandweightininoperablestageiiinsclcpatientstreatedwithconcurrentchemoradiotherapyfollowedbymaintenancetreatmentwithdurvalumab
AT ezec longitudinalchangesofbloodparametersandweightininoperablestageiiinsclcpatientstreatedwithconcurrentchemoradiotherapyfollowedbymaintenancetreatmentwithdurvalumab
AT manapovf longitudinalchangesofbloodparametersandweightininoperablestageiiinsclcpatientstreatedwithconcurrentchemoradiotherapyfollowedbymaintenancetreatmentwithdurvalumab